# US 2026/0256914 A1 · Chimeric antigen receptor and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256914 A1
- Document ID: US20260256914A1
- Status: Published application
- Kind: A1
- Application number: 19/676,865
- Filed: 2026-05-14
- Published: 2026-09-03
- Earliest claimed: 2023-11-16
- Assignees: Guangzhou Reforgene Medicine Co., Ltd.
- Applicants: Guangzhou Reforgene Medicine Co., Ltd.
- Inventors: Junbin LIANG; Zhichao MEI; Hui XU; Yubin PAN; Xiaomin ZENG
- Web page: https://patentgrep.com/patent/US20260256914A1

## CPC

- A61K 40/4261: {Proteoglycans, e.g. glypican, brevican or CSPG4}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/17: Monocytes; Macrophages
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61P 35/00: Antineoplastic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/22: Intracellular domain
- A61K 2239/53: Liver
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed is a chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises an extracellular domain, a transmembrane domain, and an intracellular domain connected in sequence; the extracellular domain recognizes and binds to an antigen; the intracellular domain comprises an activation domain, or comprises a costimulatory domain and an activation domain; and relative to a parental intracellular domain, lysines in the costimulatory domain and/or the activation domain are substituted with glycines.

## Claims

### Claim 1

A chimeric antigen receptor, comprising an extracellular domain, a transmembrane domain, and an intracellular domain connected in sequence, wherein:
the extracellular domain recognizes and binds to an antigen;
the intracellular domain comprises an activation domain, or comprises a costimulatory domain and the activation domain; and
relative to a parental intracellular domain, lysines in at least one of the costimulatory domain or the activation domain are partially or completely substituted with glycines.

### Claim 2 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the number of the costimulatory domain is at least one, and wherein:
relative to the parental intracellular domain, lysines in the activation domain are partially or completely substituted with glycines; or
relative to the parental intracellular domain, lysines in at least one of the costimulatory domain and the activation domain are partially or completely substituted with glycines.

### Claim 3 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the chimeric antigen receptor satisfies at least one of the following:
the activation domain comprises a functional signaling domain of at least one protein selected from the group consisting of CD3ζ, CD3γ, CD3δ, CD3ε, FcεRIγ, FcRβ, CD79a, CD79b, FcγRIIa, DAP10, and DAP12;
the costimulatory domain is a costimulatory domain of at least one protein selected from the group consisting of 4-1BB, CD27, CD28, OX-40, and ICOS;
the transmembrane domain is a transmembrane domain of at least one protein selected from the group consisting of CD28, CD3e, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154; or
the extracellular domain is an antibody or an antigen-binding fragment.

### Claim 4 (depends on 3)

The chimeric antigen receptor according to claim 3, wherein the chimeric antigen receptor satisfies at least one of the following:
the activation domain comprises a functional signaling domain of CD3ζ;
the costimulatory domain is a costimulatory domain of at least one selected from the group consisting of CD28 and 4-1BB;
the transmembrane domain is a transmembrane domain of CD8; or
the extracellular domain is an scFv, a single-domain antibody, or an F(ab)′.

### Claim 5 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the chimeric antigen receptor satisfies at least one of the following:
the chimeric antigen receptor further comprises a hinge region, wherein the hinge region connects the extracellular domain and the transmembrane domain;
the chimeric antigen receptor further comprises a signal peptide; or
the extracellular domain targets a tumor antigen.

### Claim 6 (depends on 5)

The chimeric antigen receptor according to claim 5, wherein the chimeric antigen receptor satisfies at least one of the following:
the hinge region comprises a hinge region of CD8α or CD28;
the signal peptide is a signal peptide of CD8α; or
the tumor antigen is selected from the group consisting of GPC3, CLDN18.2, GCC, EGFRvIII, ROR1, CLDN6, MSLN, ALPP, MUC1, LGR5, HER2, OR2H1, DLL-3, C-MET, glyco-cMET, glyco-LAMP1, CD123, CD33, CLL-1, CD70, CD38, FLT3, and GRP78.

### Claim 7 (depends on 1)

The chimeric antigen receptor according to claim 1, wherein the chimeric antigen receptor satisfies at least one of the following:
the activation domain is a functional signaling domain of CD3ζ;
the costimulatory domain is a costimulatory domain of CD28;
the transmembrane domain is a transmembrane domain of CD8;
the hinge region is a hinge region of CD8α; or
the signal peptide is a signal peptide of CD8α.

### Claim 8 (depends on 7)

The chimeric antigen receptor according to claim 7, wherein the chimeric antigen receptor satisfies at least one of the following:
the activation domain comprises an amino acid sequence set forth in SEQ ID NO: 16;
the costimulatory domain comprises an amino acid sequence set forth in at least one of SEQ ID NO: 12 or SEQ ID NO: 14;
the transmembrane domain comprises an amino acid sequence set forth in SEQ ID NO: 10;
the hinge region comprises an amino acid sequence set forth in SEQ ID NO: 8; or
the signal peptide comprises an amino acid sequence set forth in SEQ ID NO: 4.

### Claim 9 (depends on 1)

A polypeptide, comprising the chimeric antigen receptor according to claim 1, wherein the polypeptide is linked to an additional functional molecule, and wherein the additional functional molecule is selected from the group consisting of a signal peptide, a protein tag, other antigen-binding molecules, a cytokine, and combinations thereof.

### Claim 10 (depends on 1)

An isolated nucleic acid, wherein the nucleic acid encodes the chimeric antigen receptor according to claim 1 or a polypeptide comprising the chimeric antigen receptor.

### Claim 11 (depends on 10)

The nucleic acid according to claim 10, wherein the nucleic acid satisfies at least one of the following:
a nucleic acid sequence encoding the transmembrane domain of the chimeric antigen receptor is set forth in SEQ ID NO: 9;
a nucleic acid sequence encoding the activation domain of the chimeric antigen receptor is set forth in SEQ ID NO: 15;
a nucleic acid sequence encoding the costimulatory domain of the chimeric antigen receptor is set forth in at least one of SEQ ID NO: 11 or SEQ ID NO: 13;
the chimeric antigen receptor further comprises a hinge region, and a nucleic acid sequence encoding the hinge region of the chimeric antigen receptor is set forth in SEQ ID NO: 7; or
the chimeric antigen receptor further comprises a signal peptide, and a nucleic acid sequence encoding the signal peptide of the chimeric antigen receptor is set forth in SEQ ID NO: 3.

### Claim 12 (depends on 10)

A vector, comprising the nucleic acid according to claim 10, wherein the vector is a plasmid, a cosmid, a bacteriophage, or a viral vector.

### Claim 13 (depends on 10)

A gene expression cassette, comprising a promoter and the nucleic acid according to claim 10.

### Claim 14 (depends on 1)

An immune effector cell, wherein the immune effector cell expresses the chimeric antigen receptor according to claim 1 or a polypeptide comprising the chimeric antigen receptor.

### Claim 15 (depends on 14)

The immune effector cell according to claim 14, wherein the immune effector cell is selected from one or more of T cells, NK cells, NKT cells, monocytes, mast cells, macrophages, dendritic cells, CIK cells, and stem cell-derived immune effector cells.

### Claim 16 (depends on 12)

A method for preparing an immune effector cell, comprising: introducing the vector according to claim 12 or a gene expression cassette comprising the vector into a parental immune effector cell, thereby obtaining the immune effector cell.

### Claim 17 (depends on 1)

A pharmaceutical composition, comprising:
at least one of the chimeric antigen receptor according to claim 1, a polypeptide comprising the chimeric antigen receptor, a nucleic acid encoding the chimeric antigen receptor or the polypeptide, a vector comprising the nucleic acid, a gene expression cassette comprising the nucleic acid, or an immune effector cell expressing the chimeric antigen receptor or the polypeptide; and
at least one of a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient.

### Claim 18 (depends on 1)

A method of preventing or treating a tumor or cancer in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of at least one of the chimeric antigen receptor according to claim 1, a polypeptide comprising the chimeric antigen receptor, a nucleic acid encoding the chimeric antigen receptor or the polypeptide, a vector comprising the nucleic acid, a gene expression cassette comprising the nucleic acid, an immune effector cell expressing the chimeric antigen receptor or the polypeptide, or a pharmaceutical composition comprising the chimeric antigen receptor, the polypeptide, the nucleic acid, the vector, the gene expression cassette, or the immune effector cell;
wherein the tumor comprises a solid tumor or a non-solid tumor.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the solid tumor is selected from the group consisting of liver cancer, gastric cancer, lung cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, cervical cancer, kidney cancer, pancreatic cancer, liposarcoma, melanoma, adrenal cancer, schwannoma, malignant fibrous histiocytoma, and esophageal cancer; and the non-solid tumor is selected from the group consisting of B-cell lymphoma, Hodgkin's lymphoma, chronic myeloid leukemia, and acute myeloid leukemia.

### Claim 20 (depends on 1)

A composition for preventing or treating a tumor or cancer, comprising the chimeric antigen receptor according to claim 1, a polypeptide comprising the chimeric antigen receptor, a nucleic acid encoding the chimeric antigen receptor or the polypeptide, a vector comprising the nucleic acid, a gene expression cassette comprising the nucleic acid, an immune effector cell expressing the chimeric antigen receptor or the polypeptide, or a pharmaceutical composition comprising the chimeric antigen receptor, the polypeptide, the nucleic acid, the vector, the gene expression cassette, or the immune effector cell.
